復星醫藥(02196.HK)以2.49億元人幣認購聯合健康險14%股權
復星醫藥(02196.HK)公布,與南沙科金各自出資約2.49億元人民幣(下同),分別認購聯合健康險9,722萬股新股,各持14%股權,公司將以自有資金支付對價。
公司今年5月與順德科創計劃各自認購聯合健康險新股,其後順德科創基於中長期規劃等因素,不再參與認購,而由南沙科金作為新投資方參與今次增資。增資估值仍為12.8億元。
聯合健康險從事醫療保險、疾病保險、失能收入損失保險、護理保險和意外保險等業務,去年營業收入35.35億元,淨利潤6,282萬元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.